Liquidia Announces Poster Presentation at the 14th Annual World Congress of the Pulmonary Vascular Research Institute (PVRI)
January 24 2020 - 9:00AM
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a
late-stage clinical biopharmaceutical company focused on the
development and commercialization of therapeutics using its
proprietary PRINT® technology, today announced that it will
present a poster highlighting clinical data from studies of LIQ861,
treprostinil inhalation powder, to support the treatment of
pulmonary arterial hypertension (PAH) at the 14th PVRI Annual World
Congress on Pulmonary Vascular Disease in Lima, Peru.
Presentation details are as follows:
Title: |
|
|
|
Pharmacokinetic (PK) performance of LIQ861 and evaluation of
comparative bioavailability with Tyvaso® in healthy subjects |
|
|
|
|
|
Abstract Reference Number: |
|
|
|
50 |
|
|
|
|
|
Date/Time: |
|
|
|
Friday, January 31; 11:40 a.m. – 1:00 p.m. ET |
|
|
|
|
|
Location: |
|
|
|
Grand Salon 1 |
A copy of the poster will be available on the
company’s website at the time of the presentation.
About LIQ861 LIQ861 is an
inhaled dry powder formulation of treprostinil designed using
Liquidia’s PRINT® technology to enhance deep-lung delivery using a
convenient, palm-sized dry powder inhaler (“DPI”) for the treatment
of pulmonary arterial hypertension (PAH). PRINT® technology
enables development of drug particles that are precise and uniform
in size, shape, weight and composition that are engineered for
optimal deposition in the lung following oral inhalation.
Liquidia believes LIQ861 can overcome the limitations of
current inhaled therapies and has the potential to maximize the
therapeutic benefits of treprostinil in treating PAH by safely
delivering higher doses into the lungs. Liquidia has completed an
open-label, multi-center phase 3 clinical study of LIQ861 in
patients diagnosed with PAH known as INSPIRE, or Investigation of
the Safety and Pharmacology of Dry Powder Inhalation of
Treprostinil.
About Liquidia
Liquidia is a late-stage clinical
biopharmaceutical company focused on the development and
commercialization of therapeutics using its proprietary PRINT®
technology to transform the lives of patients. Currently, Liquidia
is focused on the development of two product candidates using its
PRINT particle engineering platform: LIQ861 for the treatment of
pulmonary arterial hypertension and LIQ865 for the treatment of
local post-operative pain. Having been evaluated in a phase 3
clinical trial (INSPIRE), LIQ861 is designed to improve the
therapeutic profile of treprostinil by enhancing deep-lung delivery
and achieving higher dose levels than current inhaled therapies by
using a convenient, palm-sized dry powder inhaler. LIQ865, for
which Liquidia has completed two phase 1 clinical trials, is
designed to deliver sustained-release particles of bupivacaine, a
non-opioid anesthetic, to treat local post-operative pain for three
to five days through a single administration.
Forward-Looking Statements
This press release may include forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements contained in this press release
other than statements of historical facts, including statements
regarding our future results of operations and financial position,
our strategic and financial initiatives, including the potential
licensing of LIQ861, our business strategy and plans and our
objectives for future operations, are forward-looking statements.
Such forward-looking statements, including statements regarding the
anticipated closing of the private placement, the use of proceeds
from the private placement, the filing of a registration statement
to register the resale of the shares to be issued and sold in the
private placement, clinical trials, clinical studies and other
clinical work (including the funding therefor, anticipated patient
enrollment, safety data, study data, trial outcomes, timing or
associated costs), regulatory applications and related timelines,
including the filing of a New Drug Application (NDA) for LIQ861 and
our ability to execute on our strategic or financial initiatives,
involve significant risks and uncertainties and actual results
could differ materially from those expressed or implied herein. The
words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “would,” and similar expressions are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy, short-term and long-term business
operations and objectives and financial needs, including but not
limited to whether the conditions for the closing of the private
placement will be satisfied. These forward-looking statements are
subject to a number of risks discussed in our filings with the
Securities and Exchange Commission, as well as a number of
uncertainties and assumptions. Moreover, we operate in a very
competitive and rapidly changing environment and our industry has
inherent risks. New risks emerge from time to time. It is not
possible for our management to predict all risks, nor can we assess
the impact of all factors on our business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements we may make. In light of these risks, uncertainties and
assumptions, the future events discussed in this press release may
not occur and actual results could differ materially and adversely
from those anticipated or implied in the forward-looking
statements. Nothing in this press release should be regarded as a
representation by any person that these goals will be achieved, and
we undertake no duty to update our goals or to update or alter any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact Information
Investors & Media: Jason AdairVice
President, Corporate Development and
Strategy919.328.4400jason.adair@liquidia.com
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Apr 2023 to Apr 2024